On December 10, 2020 Onxeo S.A. (ISIN: FR0010095596), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, reported the transfer of the listing of its shares from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility on December 15, 2020 (Press release, Onxeo, DEC 10, 2020, View Source [SID1234575005]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The application for the admission of Onxeo’s shares to the Euronext Growth market in Paris was approved by the Euronext Admissions Committee on December 9, 2020.
As a reminder, Onxeo had announced on July 29, 2010 its intention to transfer the listing of its shares to the Euronext Growth Paris multilateral trading facility. The transfer to Euronext Growth Paris is intended to enable Onxeo to be listed on a market more appropriate to the size of the company, to reduce the costs associated with listing, while enabling it to continue to benefit from the attractions of the financial markets.
Onxeo will continue to provide accurate, precise and truthful information, making public any inside information concerning the company, in accordance with the European Regulation on Market Abuse (MAR Regulation).
Final timetable for the transfer of listing market
The company is supported in its project of transfer to Euronext Growth by Invest Securities as Listing Sponsor.
Wednesday, December 9, 2020 - Notification by Euronext of the decision to admit the securities to Euronext Growth
Thursday, December 10, 2020 - Distribution of a press release by the Company
Friday, December 11, 2020
– Posting of the Information Document on the websites of the Company and Euronext
– Distribution of a Euronext market notice announcing the delisting of ordinary shares of Onxeo from Euronext Paris
– Distribution of a Euronext market notice announcing the admission of ordinary shares of Onxeo to Euronext Growth
Monday, December 14, 2020 - Delisting of ordinary shares of Onxeo from Euronext Paris (post-market)
Tuesday, December 15, 2020 - Admission of ordinary shares of Onxeo to Euronext Growth (at opening)
The ISIN code for identifying Onxeo securities remains unchanged (FR0010095596) and the mnemonic becomes ALONX.
In addition, Onxeo shares remain eligible for PEAs and PEA-SMEs.
The information document relating to the transfer of shares to Euronext Growth is available on the Company’s website: www.onxeo.com/investors-en/ on December 11, 2020.